CAS No. :	1197996-80-7
Formula :	C₂₁H₂₄N₂O₂
M.W :	336.43
SMILES Code :	CC(NCCN1C2=C(C3=C1C=CC(C(C)=O)=C3)C=C(C(C)=O)C=C2)C
Synonyms :	Curaxin 137; CBL-C137
MDL No. :	MFCD18071578

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

D425 cells	1 µM	24 hours	Inhibited cell proliferation and induced apoptosis	Cell Death Dis. 2020 Dec 2;11(12):1029.
ONS-76 cells	2 µM	1 hour	Enhanced sensitivity to cisplatin and radiation, reduced cell viability	Cancer Lett. 2021 Nov 1;520:201-212.
HD-MB03 cells	2 µM	1 hour	Enhanced sensitivity to cisplatin and radiation, reduced cell viability	Cancer Lett. 2021 Nov 1;520:201-212.
A1207	0.6 or 2.0 µM	1 or 16 hours	Evaluate the effect of CBL0137 on FACT, p53, and NF-ĸB. Results showed that CBL0137 caused loss of FACT subunits from the soluble protein fraction, significantly increased p53 expression, and downregulated NF-ĸB-dependent transcription.	Neuro Oncol. 2017 Feb 1;19(2):186-196.
U87MG	0.6 or 2.0 µM	1 or 16 hours	Evaluate the effect of CBL0137 on FACT, p53, and NF-ĸB. Results showed that CBL0137 caused loss of FACT subunits from the soluble protein fraction, significantly increased p53 expression, and downregulated NF-ĸB-dependent transcription.	Neuro Oncol. 2017 Feb 1;19(2):186-196.
HT1080 cells	1-2.5 µM	15 minutes	To evaluate the effect of CBL0137 on enhancer-promoter communication (EPC), results showed that CBL0137 significantly decreased transcript yield on both chromatinized and histone-free DNA templates.	Nat Commun. 2019 Mar 29;10(1):1441.
B16 NF-κB-Luc reporter cells	5 or 10 µM	15 minutes	To evaluate the inhibitory effect of CBL0137 on NF-κB pathway activity. Results showed that CBL0137 dose-dependently suppressed NF-κB pathway activity.	Cancer Res. 2016 Nov 15;76(22):6620-6630.
KELLY cells	25 µM	15 minutes	Evaluate the effect of CBL0137 and PNB on chromatin condensation	Clin Cancer Res. 2021 Aug 1;27(15):4338-4352.
RCC45	2 µM	24 hours	Evaluate the effect of CBL0137 on the cell cycle of RCC45 cells	Sci Transl Med. 2011 Aug 10;3(95):95ra74.
HDMB03 cells	1 µM	24 hours	Inhibited cell proliferation and induced apoptosis	Cell Death Dis. 2020 Dec 2;11(12):1029.
D458 cells	1 µM	24 hours	Inhibited cell proliferation and induced apoptosis	Cell Death Dis. 2020 Dec 2;11(12):1029.
B16 melanoma cells	0.7, 1.4, 2.8, or 5.6 µM	15 or 30 minutes	To evaluate the in vitro cytotoxic effects of CBL0137 on B16 melanoma cells. Results showed that CBL0137 significantly reduced tumor cell viability at both 15 and 30 minutes of treatment in a dose-dependent manner.	Cancer Res. 2016 Nov 15;76(22):6620-6630.
BE(2)-C cells	100 nM, 200 nM	20 hours	Evaluate the effect of CBL0137 on PNB-induced DNA damage repair	Clin Cancer Res. 2021 Aug 1;27(15):4338-4352.
Murine Embryonic Fibroblasts (MEFs)	5 µM	24 hours	CBL0137 induced ZBP1-dependent cell death by triggering Z-DNA formation and activating ZBP1-mediated necroptosis.	Nature. 2022 Jun;606(7914):594-602.
NK-92 cells	500 nM	24 hours	To investigate the effect of CBL0137 on NK cell activation, results showed that CBL0137 significantly enhanced NK cell-mediated killing function.	Nucleic Acids Res. 2022 Aug 26;50(15):8700-8718.
HeLa cells	500 nM	24 hours	To investigate the inhibitory effect of CBL0137 on ZIKV and influenza A virus infection, results showed that CBL0137 effectively inhibited viral infection.	Nucleic Acids Res. 2022 Aug 26;50(15):8700-8718.
HEK293T cells	100, 200, 500 nM	24 hours	To investigate the induction of IFN signaling by CBL0137, results showed that CBL0137 significantly increased the expression of IFNs and ISGs.	Nucleic Acids Res. 2022 Aug 26;50(15):8700-8718.
NDFs	0.5 µM	24 hours	To evaluate the effect of CBL0137 on the transcriptome of normal dermal fibroblasts. Results showed that CBL0137 at 0.5 μM induced widespread transcriptional changes, which were similar in p53-positive and negative cells.	Nucleic Acids Res. 2023 Nov 27;51(21):11836-11855.
HT1080	0.5 µM	24 hours	To evaluate the effect of CBL0137 on the transcriptome of HT1080 cells. Results showed that CBL0137 at 0.5 μM induced widespread transcriptional changes, which were similar in p53-positive and negative cells.	Nucleic Acids Res. 2023 Nov 27;51(21):11836-11855.
NDFs	1 µM	24 hours	To evaluate the toxicity of CBL0137 on normal dermal fibroblasts and its effect on p53 activation. Results showed that CBL0137 induced p53 protein accumulation at concentrations of 0.5-1 μM and caused cell death at higher concentrations.	Nucleic Acids Res. 2023 Nov 27;51(21):11836-11855.
HT1080	1 µM	24 hours	To evaluate the toxicity of CBL0137 on HT1080 cells and its effect on p53 activation. Results showed that CBL0137 induced p53 protein accumulation at concentrations of 0.5-1 μM and caused cell death at higher concentrations.	Nucleic Acids Res. 2023 Nov 27;51(21):11836-11855.
Jeko-1	0.5-2.0 µM	24 hours	To evaluate the inhibitory effect of CBL0137 on B-NHL cell proliferation, results showed that CBL0137 significantly inhibited B-NHL cell proliferation in a concentration and time-dependent manner.	Cell Commun Signal. 2023 Jan 23;21(1):16.
Raji	0.5-2.0 µM	24 hours	To evaluate the inhibitory effect of CBL0137 on B-NHL cell proliferation, results showed that CBL0137 significantly inhibited B-NHL cell proliferation in a concentration and time-dependent manner.	Cell Commun Signal. 2023 Jan 23;21(1):16.
Farage	0.5-2.0 µM	24 hours	To evaluate the inhibitory effect of CBL0137 on B-NHL cell proliferation, results showed that CBL0137 significantly inhibited B-NHL cell proliferation in a concentration and time-dependent manner.	Cell Commun Signal. 2023 Jan 23;21(1):16.
SU-DHL-4	0.5-2.0 µM	24 hours	To evaluate the inhibitory effect of CBL0137 on B-NHL cell proliferation, results showed that CBL0137 significantly inhibited B-NHL cell proliferation in a concentration and time-dependent manner.	Cell Commun Signal. 2023 Jan 23;21(1):16.
BJ fibroblasts	1 µM	3 hours	Induced degradation of POLR2A without affecting POLR1A degradation	Nucleic Acids Res. 2024 May 8;52(8):4151-4166.
U2OS cells	1 µM	3 hours	Induced degradation of POLR2A, with a progressive consumption of form IIa and reduction in Ser5 and Ser2 phosphorylation of POLR2A	Nucleic Acids Res. 2024 May 8;52(8):4151-4166.
Human Fibroblasts (HS68)	5 µM	36 hours	CBL0137 induced Z-DNA formation and ZBP1-dependent cell death in HS68 cells.	Nature. 2022 Jun;606(7914):594-602.
MB52	300 nM	48 hours	To evaluate the effect of CBL0137 on apoptosis and cell cycle in DPM cells, results showed that CBL0137 induced apoptosis and G2-M phase cell cycle arrest.	J Exp Clin Cancer Res. 2023 Nov 16;42(1):304.
H2373	300 nM	48 hours	To evaluate the effect of CBL0137 on NF-κB and p53, results showed that CBL0137 inhibited NF-κB and activated p53.	J Exp Clin Cancer Res. 2023 Nov 16;42(1):304.
T. brucei Lister 427	0.038 µM	48 hours	Evaluate the inhibitory activity of CBL0137 against T. brucei, with an EC50 of 0.038 μM.	J Med Chem. 2023 Feb 9;66(3):1972-1989.
Non-cancerous ovarian epithelial cells (HOSE6.3, HOSE17.1)	0-2.5 µM	6 days	Evaluate the growth inhibitory activity of CBL0137 on non-cancerous ovarian epithelial cells, showing no significant growth inhibitory effect.	J Exp Clin Cancer Res. 2022 Dec 21;41(1):355.
Patient-derived tumor cells (DF20, DF68, DF86, DF101, DF106, DF149, DF181)	0-2.5 µM	6 days	Evaluate the growth inhibitory activity of CBL0137 on patient-derived tumor cells, showing significant anti-growth activity against SSRP1-high tumor cells with IC50 values of 0.3–1.3 μM.	J Exp Clin Cancer Res. 2022 Dec 21;41(1):355.
HGSC cell lines (OVCAR-8, OVCAR-4, OVCAR-3, Kuramochi, CAOV3, OV90, OAW42, PEO1, PEO4)	0-2.5 µM	6 days	Evaluate the growth inhibitory activity of CBL0137 on HGSC cell lines, showing significant anti-growth activity against SSRP1-high HGSC cell lines with IC50 values of 0.2–0.6 μM.	J Exp Clin Cancer Res. 2022 Dec 21;41(1):355.
HeLa	2 µM	6 hours	Evaluate the effect of CBL0137 on DNA damage in HeLa cells	Sci Transl Med. 2011 Aug 10;3(95):95ra74.
MM1.S cells	0.3-3 µM	6 hours	To analyze the effect of CBL0137 on gene expression profiles, results showed that CBL0137 strongly inhibited transcription regulated by enhancers or super-enhancers.	Nat Commun. 2019 Mar 29;10(1):1441.
GBM 08-387	150 nM	6 hours	Evaluate the effect of CBL0137 combined with radiotherapy on cell growth, results showed that combination treatment significantly reduced cell growth	Cancer Lett. 2021 Feb 28;499:232-242.
GBM 3691	150 nM	6 hours	Evaluate the effect of CBL0137 combined with radiotherapy on cell growth, results showed that combination treatment significantly reduced cell growth	Cancer Lett. 2021 Feb 28;499:232-242.
GBM 1016	150 nM	6 hours	Evaluate the effect of CBL0137 combined with radiotherapy on cell growth, results showed that combination treatment reduced cell growth but did not reach statistical significance	Cancer Lett. 2021 Feb 28;499:232-242.
GBM NU757	150 nM	6 hours	Evaluate the effect of CBL0137 combined with radiotherapy on cell growth, results showed that combination treatment significantly reduced cell growth	Cancer Lett. 2021 Feb 28;499:232-242.
Non-stem tumor cells (NSTCs)	100-600 nM	72 hours	To evaluate the cytotoxic effect of CBL0137 on NSTCs, results showed NSTCs were also sensitive to CBL0137 but less so than GSCs.	Cancer Res. 2016 Apr 15;76(8):2432-42.
GBM stem cells (GSCs)	100-600 nM	72 hours	To evaluate the cytotoxic effect of CBL0137 on GSCs, results showed GSCs were highly sensitive to CBL0137.	Cancer Res. 2016 Apr 15;76(8):2432-42.
H2052	200-380 nM	72 hours	To evaluate the killing effect of CBL0137 on DPM cells, results showed that CBL0137 effectively killed DPM cells at low concentrations.	J Exp Clin Cancer Res. 2023 Nov 16;42(1):304.
H526 non-TICs	250 nM	72 hours	Evaluate the effect of CBL0137 combined with Rova-T on cell survival of H526 non-TICs, results showed no additional effect on non-TICs	Br J Cancer. 2021 Mar;124(5):893-895.
H82 non-TICs	250 nM	72 hours	Evaluate the effect of CBL0137 combined with Rova-T on cell survival of H82 non-TICs, results showed no additional effect on non-TICs	Br J Cancer. 2021 Mar;124(5):893-895.
HT1080	0.8 µM	8 hours	Evaluate the p53 activation effect of CBL0137 on HT1080 cells	Sci Transl Med. 2011 Aug 10;3(95):95ra74.
H526 TICs	250 nM	72 hours	Evaluate the effect of CBL0137 combined with Rova-T on cell survival of H526 TICs, results showed significant reduction in cell survival	Br J Cancer. 2021 Mar;124(5):893-895.
H82 TICs	250 nM	72 hours	Evaluate the effect of CBL0137 combined with Rova-T on cell survival of H82 TICs, results showed significant reduction in cell survival	Br J Cancer. 2021 Mar;124(5):893-895.
HCT116-p53 null	1 µM	8 hours	Evaluate the activation effect of CBL0137 on p53 mutants in HCT116-p53 null cells	Sci Transl Med. 2011 Aug 10;3(95):95ra74.

C57BL/6 mice	B16 melanoma subcutaneous xenograft model	Isolated limb perfusion (ILP), intravenous injection (i.v.), or intra-arterial infusion (IAI)	0.1, 0.25, 0.5 or 1 mg (ILP); 80 mg/kg (i.v.)	Single 15 or 30 minutes (ILP); Single or once weekly for up to 4 weeks (i.v.)	To evaluate the antitumor efficacy and toxicity of CBL0137 via different administration routes in a B16 melanoma model. Results showed that CBL0137 delivered by ILP exhibited antitumor activity comparable to melphalan at doses corresponding to only a fraction of the systemic MTD, with lower toxicity. Intra-arterial infusion (IAI) of CBL0137 also demonstrated significant antitumor efficacy and safety.	Cancer Res. 2016 Nov 15;76(22):6620-6630.
NSG mice	Orthotopic GBM model	Oral	0.5 mg/mL	Replaced every 7 days, continuous treatment	To evaluate the therapeutic effect of CBL0137 on GBM mouse models, results showed CBL0137 significantly prolonged survival.	Cancer Res. 2016 Apr 15;76(8):2432-42.
Nude mice	Subcutaneous and orthotopic GBM models	Intraperitoneal (subcutaneous), intravenous (orthotopic)	10 mg/kg (subcutaneous), 70 mg/kg (orthotopic)	Daily for 7 days (subcutaneous); once a week for four weeks (orthotopic)	Evaluate the effect of CBL0137 combined with radiotherapy on survival and cancer stem cell frequency, results showed that combination treatment significantly prolonged survival and reduced cancer stem cell frequency	Cancer Lett. 2021 Feb 28;499:232-242.
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice	Subcutaneous xenograft model	Oral gavage	20 mg/kg	Twice a week for 3 weeks	To evaluate the anti-tumor effect of CBL0137 in vivo, results showed that CBL0137 significantly suppressed tumor growth and prolonged survival.	J Exp Clin Cancer Res. 2023 Nov 16;42(1):304.
C57BL/6J mice	B16-F10 melanoma model	Intratumoral injection	20 μM	Every two days for a total of 4 doses	CBL0137 significantly reversed immune checkpoint blockade (ICB) unresponsiveness by inducing ZBP1-dependent necroptosis in fibroblasts of the tumor microenvironment (TME).	Nature. 2022 Jun;606(7914):594-602.
Nude mice	Orthotopic U87MG and A1207 glioblastoma models	Oral or intravenous	25 mg/kg orally, 70 or 90 mg/kg intravenously	Various regimens: oral daily, intravenous every 4 days or once weekly for 4 weeks	Evaluate the therapeutic effect of CBL0137 on glioblastoma. Results showed that intravenous administration of CBL0137 significantly prolonged survival, increased tumor cell apoptosis, and suppressed proliferation. Oral administration showed limited efficacy.	Neuro Oncol. 2017 Feb 1;19(2):186-196.
Mice	Human tumor xenograft model	Oral gavage	30 mg/kg	5 days on/2 days off schedule for up to 4 weeks	Evaluate the antitumor effect of CBL0137 in mouse xenograft models	Sci Transl Med. 2011 Aug 10;3(95):95ra74.
Nude mice	Mammary fat pad injection model	Oral gavage	30 mg/kg	Five days a week for six weeks	Evaluate the inhibitory effect of CBL0137 on TONSL-amplified breast cancer cell lines in vivo	Cancer Res. 2023 Apr 14;83(8):1345-1360
Nude mice	Subcutaneous tumor xenograft model	Intraperitoneal injection	30 mg/kg CBL0137 and 2 mg/kg cisplatin	Every other day for four weeks	Significantly suppressed MB tumor growth	Cancer Lett. 2021 Nov 1;520:201-212.
Mice (C57BL/6, NRG, NSG)	ID8 (p53−/− BRCA1−/−) HGSC model and HGSC PDX models (DF86, DF149, LP28)	Intravenous (IV) or intraperitoneal (IP)	30-60 mg/kg	Once per week for 2 weeks	Evaluate the anti-tumor activity of CBL0137 monotherapy in HGSC models, showing significant reduction in ascitic fluid volume and tumor nodules, and prolonged survival of mice.	J Exp Clin Cancer Res. 2022 Dec 21;41(1):355.
Mice	TH-MYCN+/+ mouse model	Intravenous injection	60 mg/kg	Every 4 days for 8 doses	Evaluate the inhibitory effect of CBL0137 on neuroblastoma growth	Sci Transl Med. 2015 Nov 4;7(312):312ra176.
NOD scid IL-2 receptor gamma knockout (NSG) mice	SCLC PDX model	Intraperitoneal (Rova-T), intravenous (CBL0137)	60 mg/kg (CBL0137), 1.8 mg/kg (Rova-T)	Once weekly (CBL0137), until tumor volume reached ~1200 mm³	Evaluate the anti-tumor efficacy of CBL0137 combined with Rova-T in SCLC PDX model, results showed significant tumor growth inhibition and prolonged survival	Br J Cancer. 2021 Mar;124(5):893-895.
BALB/c nude mice	BE(2)-C neuroblastoma xenograft model	Intravenous CBL0137, intraperitoneal PNB	60 mg/kg CBL0137, 5 mg/kg PNB	CBL0137 every 4 days for 8 doses, PNB for 7 consecutive days	Evaluate the effect of CBL0137 and PNB combination on tumor growth in neuroblastoma xenograft models	Clin Cancer Res. 2021 Aug 1;27(15):4338-4352.
Nude mice	Orthotopic intracranial xenograft model	Intravenous injection	70 mg/kg	Every four days for 28 days	Significantly suppressed tumor growth and prolonged survival	Cell Death Dis. 2020 Dec 2;11(12):1029.
Swiss-Webster mice	Mouse model of chronic HAT	Oral	80 mg/kg	Once daily for 10 days	Evaluate the efficacy of CBL0137 in a mouse model of chronic HAT, showing a 165-fold reduction in parasite tissue load.	J Med Chem. 2023 Feb 9;66(3):1972-1989.

NCT01905228	Solid Tumors\|Glioblastoma	PHASE1	COMPLETED	2025-06-19	Roswell Park Cancer Institute,... More >> Buffalo, New York, 14263, United States\|University Hospital of Cleveland, Cleveland, Ohio, 44106, United States\|Cleveland Clinic, Cleveland, Ohio, 44195, United States\|CTRC at The University of Texas Healh Science Center at San Antonio, San Antonio, Texas, 78229, United States Less <<
NCT02931110	Hematological Malignancies	PHASE1	TERMINATED	2025-10-20	The Oncology Institute of Hope... More >> & Innovation, Whittier, California, 90603, United States\|Claude Sportes, Augusta, Georgia, 30912, United States\|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States\|University Hospitals Case Medical, Cleveland, Ohio, 44106, United States Less <<

{[proInfo.proName]}

CAS No.: 1197996-80-7

{[proInfo.proName]}

CAS No.: 1197996-80-7

Alternative Products

Product Details of CBL0137

Safety of CBL0137

Related Pathways of CBL0137

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	2.97mL 0.59mL 0.30mL	14.86mL 2.97mL 1.49mL	29.72mL 5.94mL 2.97mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed